Results 21 to 30 of about 34,664 (179)

Multiplex PCR-Based Neutralization (MPBN) Assay for Titers Determination of the Three Types of Anti-Poliovirus Neutralizing-Antibodies

Vaccines, 2020
Determination of poliovirus-neutralizing antibodies is an important part of clinical studies of poliovirus vaccines, epidemiological surveillance and seroprevalence studies that are crucial for global polio eradication campaigns.
Hasmik Manukyan, Svetlana Petrovskaya, Konstantin Chumakov, Majid Laassri   +3 more
doaj   +1 more source

Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey

BMC Infectious Diseases, 2022
Background Vaccination efforts to eradicate polio currently focus on children under 5 years of age, among whom most cases of poliomyelitis still occur. However, in the Democratic Republic of the Congo (DRC), an outbreak of wild poliovirus type 1 occurred
Vivian H. Alfonso, Arie Voorman, Nicole A. Hoff, William C. Weldon, Sue Gerber, Adva Gadoth, Megan Halbrook, Amelia Goldsmith, Patrick Mukadi, Reena H. Doshi, Guillaume Ngoie-Mwamba, Trevon L. Fuller, Emile Okitolonda-Wemakoy, Jean-Jacques Muyembe-Tamfum, Anne W. Rimoin   +14 more
doaj   +1 more source

PREVALENCE OF NEUTRALIZING ANTIBODIES AGAINST POLIOVIRUS 1, 2, AND 3 IN HEALTHCARE PROFESSIONALS AGED 20-50 YEARS

Revista Paulista de Pediatria, 2021
Objective: To describe the prevalence of neutralizing antibodies against poliovirus (PV1, PV2, and PV3) in blood samples of healthcare professionals aged 20 to 50 years.
José Cassio de Moraes, Maria Josefa Penon Rujula, Marcelo Otsuka   +2 more
doaj   +2 more sources

First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus

International Journal of Infectious Diseases, 2019
This is the first report of persistent oropharyngeal mucosal infection with type 2 poliovirus (iVDPV2) in a primary immune deficient patient (PID) after wild type 2 poliovirus eradication. The iVDPV2 also established persistence in the gut.
Merav Weil, Galia Rahav, Raz Somech, Tali Stauber, Jacqueline Alfandari, Leah Weiss, Ilana Silberstein, Victoria Indenbaum, Itay Bar Or, Ella Mendelson, Danit Sofer, Lester M. Shulman   +11 more
doaj   +1 more source

Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children

BMC Research Notes, 2017
Background Poliomyelitis is an acute viral infection caused by poliovirus and transmitted via the fecal–oral route. The causative agent is one of the three serotypes of poliovirus (serotypes 1, 2, 3) that differ slightly in capsid protein.
Joanne Hassan, Laura Wangai, Peter Borus, Christopher Khayeka–Wandabwa, Lucy Wanja Karani, Mercy Kithinji, Michael Kiptoo   +6 more
doaj   +1 more source

Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2

Frontiers in Medicine, 2021
Background: Millions have been exposed to SARS-CoV-2, but the severity of resultant infections has varied among adults and children, with adults presenting more serious symptomatic cases.
Brittany A. Comunale, Lilly Engineer, Lilly Engineer, Yong Jiang, John C. Andrews, Qianna Liu, Lyuqing Ji, James T. Yurkovich, Roderick A. Comunale, Qiyi Xie   +9 more
doaj   +1 more source

Antiviral Development for the Polio Endgame: Current Progress and Future Directions

Pathogens
As the world is approaching the eradication of wild poliovirus serotype 1, the last of the three wild types, the question of how to maintain a polio-free world becomes imminent.
Hang Xie, Eric E. Rhoden, Hong-Mei Liu, Folake Ogunsemowo, Bernardo A. Mainou, Rachel M. Burke, Cara C. Burns   +6 more
doaj   +1 more source

Establishment of a Poliovirus Containment Program and Containment Certification Process for Poliovirus-Essential Facilities, United States 2017–2022

Pathogens
Upon declaration of poliovirus (PV) type 2 eradication in 2015, the World Health Organization (WHO) published PV containment requirements in the Global Action Plan III (GAPIII) for mitigating the risk of a facility-associated release post eradication. In
Christy Ottendorfer, Bryan Shelby, Cecelia A. Sanders, Anna Llewellyn, Christy Myrick, Christye Brown, Suganthi Suppiah, Kortney Gustin, Lia Haynes Smith   +8 more
doaj   +1 more source

Surveillance of Acute Flaccid Paralysis (AFP) in Greece: 2008–2024

Pathogens
As part of the WHO’s Global Polio Eradication Initiative, acute flaccid paralysis (AFP) surveillance in children under 15 years old is crucial for monitoring the emergence of polioviruses and tracking Non-Polio Enteroviruses (NPEVs).
Stavroula Labropoulou, Theano Georgakopoulou, Vahid Baniasadi, Giota Mpizta, Stella Vorre, Maria Theodoridou, Mary Emmanouil, Emmanouil Angelakis   +7 more
doaj   +1 more source

Identification Epitope on VP4 Protein of Senecavirus A Recognized by a Monoclonal Antibody

Animal Research and One Health, EarlyView.
This study aims to identify conserved antigenic epitopes on the SVA VP4 protein using monoclonal antibodies, providing valuable tools for further exploring its functions and developing detection methods. SVA VP4 protein was expressed in Escherichia coli and purified with High‐Affinity Ni‐Charged Resin FF.
Liang Meng, Xuyan Xiang, Xinyu Qi, Hanrong Zhou, Peiyu Xiao, Fandan Meng, Tongqing An, Haiwei Wang   +7 more
wiley   +1 more source